Cart
sales@molnova.com
GSK8573
CAS No. 1693766-04-9
GSK8573( —— )
Catalog No. M22027 CAS No. 1693766-04-9
GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 50 | In Stock |
|
| 5MG | 80 | In Stock |
|
| 10MG | 132 | In Stock |
|
| 25MG | 248 | In Stock |
|
| 50MG | 370 | In Stock |
|
| 100MG | 537 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK8573
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
-
DescriptionGSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
-
In VitroGSK8573 (1.0 μM) has binding activity to BRD9 with a Kd value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain family.
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorBRD9
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1693766-04-9
-
Formula Weight323.39
-
Molecular FormulaC20H21NO3
-
Purity>98% (HPLC)
-
SolubilityDMSO:22 mg/mL (68.03 mM; Need ultrasonic)
-
SMILESCCCOC1=CC2=C(C=C(N2C=C1)C(C)=O)C1=CC(OC)=CC=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Chen P, et al. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B. J Med Chem. 2016 Feb 25;59(4):1410-24.
molnova catalog
related products
-
CTB
CTB (Cholera Toxin B subunit) is an activator of p300 histone acetyltransferase and induces apoptosis in MCF-7 cells.
-
ZEN-3694
ZEN-3694 (ZEN 3694) is a bromo-structural domain extra-terminal inhibitor (BETi) with activity in androgen signaling inhibitor (ASI) resistance models and can be used in combination with enzalutamide to study metastatic desmoplasia-resistant prostate cancer.
-
SR-0813
SR-0813 is a potent and selective inhibitor of the YEATS domain in ENL/AF9, with an IC50 of 25 nM and EC50 of 205 nM for the ENL YEATS domain, and an IC50 of 311 nM and EC50 of 76 nM (CETSA) for the AF9 YEATS domain.
